Response to Tyrosine Kinase Inhibitors in Real-World Patients With Chronic Myeloid Leukemia.

Approximately 60% of our RWPs would have been excluded from the pivotal phase 3 TKI trials. These data suggest that RWPs require more precise dosing to achieve CML clinical milestones and to mitigate AEs, but findings should be validated prospectively.